Related Experiment Video
Updated: May 22, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model
Xiaoling Ni1, Jingxuan Yang, Min Li
1The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA.
Abstract:
Pancreatic cancer is the fourth leading cause of cancer related deaths in North America. The poor survival statistics are due to the fact that there are no reliable tests for early diagnosis and no effective therapies once metastasis has occurred. Surgical resection is the only curative treatment for pancreatic cancer; however, only less than 15% of the patients are eligible for surgery at diagnosis. New therapies are urgently needed for this malignant disease. And combinational therapy including surgery, chemotherapy and molecular targeted therapy may further improve the efficacy of individual therapies. However, a reliable mouse model which mimics the human disease and can be used for testing the surgical treatment and surgery-based combinational therapy is not available. In this study, we have established a mouse model for curative surgical resection of pancreatic cancer. Human pancreatic cancer cells were used to create orthotopic xenografts in nude mice, distal pancreatectomy was performed using imaging-guided technology to remove the pancreatic tumors, and sham surgery was performed in the control group. All mice survived the operation and no complication was observed. Surgical resection at early stage improved the survival rate and quality of life of the mice compared with the sham surgery and surgical resection at the late stage. If combined with other therapies such as chemotherapy and molecular targeted therapy, it could further improve the outcome of pancreatic cancer. This mouse model is a useful tool to study the surgical therapy and the tumor recurrence of pancreatic cancer, and could potentially impact the therapeutic choices for this deadly disease.
Insights
A new mouse model for pancreatic cancer enables testing of surgical treatments. Early-stage surgical resection significantly improved survival, highlighting its potential in combination therapies for this deadly disease.
Area of Science:
- Oncology
- Surgical Research
- Animal Models
Background:
- Pancreatic cancer is a leading cause of cancer death with poor survival rates.
- Current diagnostic methods lack early detection capabilities, and metastatic disease has limited effective therapies.
- Surgical resection is the only cure, but few patients are candidates at diagnosis.
Purpose of the Study:
- To establish a reliable mouse model for evaluating curative surgical resection of pancreatic cancer.
- To assess the efficacy of early-stage surgical intervention and its potential in combination therapies.
- To provide a tool for studying pancreatic cancer recurrence and surgical treatment strategies.
Main Methods:
- Orthotopic xenografts of human pancreatic cancer cells were created in nude mice.
- Imaging-guided distal pancreatectomy was performed for tumor resection; sham surgery served as a control.
- Survival rates and quality of life were monitored post-surgery.
Main Results:
- The developed mouse model demonstrated successful surgical resection without complications.
- Early-stage surgical resection significantly improved survival and quality of life compared to late-stage resection and sham surgery.
- The model supports further investigation into combinational therapies including chemotherapy and molecular targeted therapy.
Conclusions:
- A novel, reliable mouse model for pancreatic cancer surgical research has been established.
- Early surgical intervention in this model shows promising survival benefits.
- This model can advance the study of surgical treatments and combination therapies for pancreatic cancer.
